Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multi-cohort, Randomized, Phase II Study of Irinotecan Liposome Combined With 5-FU / LV and Oxaliplatin for Resectable Pancreatic Cancer With or Without Addebelizumab

NCT06172036 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06172036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06172036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multi-cohort, Randomized, Phase II Study of Irinotecan Liposome Combined With 5-FU / LV and Oxaliplatin for Resectable Pancreatic Cancer With or Without Addebelizumab
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 20, 2024
Completion date
January 20, 2027
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant chemotherapy, resectable pancreatic cancer